Psoriasis is a chronic skin disease that results from the complex interaction between genetic and environmental factors. 1 Over the last few decades, scientific evidence has shown that the keratinocyte proliferation that characterizes psoriasis is triggered by activated T-cells, thus redirecting the focus of therapeutic studies to the immunologic pathways contributing to its pathogenesis.
2 This led to the biologic boom that we are currently experiencing, with the development and approval of progressively more selective targeted biological therapies and ongoing clinical trials of increasingly specific drugs, given their important implications for long-term efficacy and safety.
The major pathogenic pathways involved in psoriasis that scientific research has brought to light so far comprise: the one involving interleukin (IL)-12, composed of two subunits (p40 and p35), driving a Thelper (Th)1 response; the IL-23/IL-17 axis, the former composed by the p40 and p19 subunits and the later with two isoforms, A and F, stimulating the expansion of Th17 and Th22 cells and production of IL-17 and IL-22 -now known to have key effects on the epidermis and upregulating other proinflammatory cytokines and growth factors, therefore creating a self-amplifying inflammatory process; and tumor necrosis factor (TNF)-α signaling, a pleiotropic cytokine pathway that activates multiple immune cell types of both innate and adaptive immunity ( Figure 1 ).
1,2
The first biologic therapies, namely alefacept and efalizumab (withdrawn), acted by blocking Tcells, suppressing overall cytokine production and thus inhibiting the activation and proliferation of all T-cell subtypes, with a broad effect on the immune system and, consequently, wide-ranging potential side effects. [2] [3] [4] This prompted unceasing investigation for more selective drugs.
TNF-α is a potent pro-inflammatory cytokine with significant interactions with the other pathogenic cytokines in psoriasis. Its blockade is thought to improve psoriasis due to its impact in down-regulating IL-23, Th-17 cells, and, later, Th-1 related genes.
5 Etanercept, adalimumab, and infliximab are approved for psoriasis, and new drugs are currently undergoing clinical trials. As TNF-α plays also an important role in innate immunity, resulting in broad immunosuppression, the risk of infection and malignancy with these therapies cannot be disregarded.
5
Available anti-IL-12/IL-23 therapies, such as ustekinumab, target the p40 subunits of the two cytokines.
6 Both the p19 and p40 subunits of IL-23 are amplified in psoriasis, unlike IL-12p35, which is not elevated; this suggests that IL-23 might have greater Pinto-Almeida T, Torres T impact in psoriasis than IL-12.
2 These drugs directly inhibit T-cell activation, unlike anti-TNFα preparations, which act indirectly through the inhibition of IL-23 by dendritic cells.
2 Besides, the innate immunity is not directly suppressed by inhibition of p40, with a theoretically superior safety profile. Although more selective, an additional refinement regarding this inflammatory axis recently emerged, with an alternate targeting of the p19 subunit of IL-23 alone, sparing the p40 subunit and, consequently, not affecting the Th-1 driven response.
2 This new approach and inhibition of the IL-23 are currently being tested in phase II clinical trials, in order to assess the potential benefits of guselkumab and tildrakizumab. Regarding IL-17 inhibition, secukinumab is currently in phase III trials and ixekinumab in phase II. 7, 8 Only the IL-17A isoform is targeted; according to recent data, this approach has the advantage of maintaining a high efficacy of blockade of this major cytokine with a low risk of adverse events resulting from immunosuppression, probably due to compensatory action by the other isoform, although the clinical significance of these facts is not completely elucidated. 7, 8 Nevertheless, acting selectively at the level of a key effector cytokine might preserve the other cellular immune functions, so the spectrum of immunosuppression is undoubtedly narrower than with any previous therapy, and the targeted molecules much more specific to the pathogenesis of psoriasis, making this a promising drug. IL-17 receptor blockers, such as brodalumab, are also under phase II trials, with the same potential benefits of the aforementioned agents, but inhibiting multiple members of the IL-17 family and so with a different side effect profile (which has yet to be elucidated). 9 Other possible pathways are under the scrutiny of laboratory investigation, and IL-22 has appeared as a promising target. It is strictly related to the critical Th17/Th22 pathway, thus making it a smart option for the therapy of psoriasis.
10 Nevertheless, trials of fezakinumab, an IL-22 antibody, were discontinued.
10
In the era of biologics and with the advent of genetic and molecular research, therapy targets are becoming progressively more selective. The recognition of the major pathogenic pathways involved in psoriasis and the knowledge of their clinical implica- tions prompted the emergence of numerous novel therapies. The goal remains to achieve selective immunosuppression with minimal side effects, as the further downstream the target of blockade in the inflammatory cascade, the lower the resultant immunosuppression and the consequent risks of infection and malignancy. Agents once considered selective only some years ago will probably soon be replaced by more recent and more focused therapies. If we think we have come too far, much remains to be done in the future, and further large, controlled studies of recent drugs are needed to clarify their role in the complex management of psoriasis. q
